CYP1A2 is an enzyme primarily known for metabolizing caffeine, but it also plays a role in estrogen breakdown. During menopause, estrogen levels drop, contributing to symptoms like hot flashes and sleep disturbances. Some research suggests that CYP1A2 variants affect caffeine metabolism speed – fast metabolizers may process caffeine differently, potentially influencing symptom triggers. However, the evidence is weak: no robust clinical trials directly support using CYP1A2 testing for menopause management. Consumer DNA tests like those from MyBody-X provide lifestyle insights, not medical diagnoses. Adjusting caffeine intake might help some women, but this should be based on personal experience rather than genetic results alone. For significant symptoms, consult a gynecologist or endocrinologist. Evidence: mechanistic/unclear.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-4a435f11edf8afe42d06788a